News

Doctors in the Netherlands are using the VMS Heart Analysis System, developed by Ventripoint Diagnostics, for early diagnosis of pulmonary hypertension (PH) in sarcoidosis patients. Approximately 500 patients with sarcoidosis have been tested, using the VMS Heart Analysis System for detecting PH at an early stage. Marco Post,…

Treatment of pulmonary arterial hypertension (PAH) with Tracleer (bosentan) may be more cost-effective than epoprostenol medications or palliative care, but less than Revatio (sildenafil) and other endothelin receptor blockers, a review study suggests. The study, “Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A…

Tracleer (bosentan) treatment improves mean pulmonary arterial pressure (mPAP) in β-thalassemia patients with potential pulmonary arterial hypertension (PAH), according to a case report of three patients. The report, “The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension,”…

Long-term treatment with Adempas (riociguat) can reduce right heart size and improve the heart’s pumping function in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), results from a retrospective study suggest. The study, “Right ventricular size and function under riociguat…

Treatment with INOpulse for eight weeks is safe and provides clinically meaningful improvements in physical activity in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to top-line results of an ongoing Phase 2b trial. The results are from the first group of Bellerophon Therapeutics’…

With the goal of enhancing the lives of pulmonary hypertension (PH) patients, including through better medical care, the nonprofit Team PHenomenal Hope (Team PH) is accepting applications for early-career research grants of up to $50,000. The organization’s newly created grant program — PHenomenal Impact Fund for Global PH…

Repeated measurements of different biomarkers over time offer a better risk prediction than single measurements for pulmonary arterial hypertension (PAH) associated with congenital heart disease, a study reports. The study, “Prognostic value of multiple repeated biomarkers in pulmonary arterial hypertension associated with congenital heart disease,” was published in…

Pulmonary hypertension (PH) patients in China, the world’s most populous nation, finally have their own advocacy organization. The iSEEK Pulmonary Hypertension Hope Center, whose website is available only in Chinese for the moment, is located in the Xicheng district of Beijing, China’s capital city. It is run by Huan…

Worse measures of blood flow, arterial oxygenation, and cardiac function may underlie the poor clinical condition of chronic thromboembolic pulmonary hypertension (CTEPH) patients who also have obstructive sleep apnea (OSA), according to a new study. The research, “Obstructive sleep apnea in patients with chronic thromboembolic pulmonary…

Throughout the past year, Pulmonary Hypertension News has brought you information about important discoveries, treatment developments, clinical trials, and other events dealing with pulmonary hypertension (PH). As we look ahead to 2019, here are the 10 most-read stories of 2018, with a summary of their significance to PH patients, family…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Biotechnology company Morphogen-IX has raised $23.2 million to advance development of its lead drug candidate, MGX292, for the treatment of pulmonary arterial hypertension (PAH). The investment, led by Medicxi with contributions from …